Genomic Health Inc (NASDAQ:GHDX) Institutional Investors Sentiment Index Up in 2017 Q4

April 17, 2018 - By Henry Gaston

Genomic Health, Inc. (NASDAQ:GHDX) Logo

Sentiment for Genomic Health Inc (NASDAQ:GHDX)

Genomic Health Inc (NASDAQ:GHDX) institutional sentiment decreased to 1.13 in 2017 Q4. Its down -1.19, from 2.32 in 2017Q3. The ratio dived, as 60 institutional investors started new and increased holdings, while 53 reduced and sold stakes in Genomic Health Inc. The institutional investors in our partner’s database now have: 31.21 million shares, up from 30.86 million shares in 2017Q3. Also, the number of institutional investors holding Genomic Health Inc in their top 10 holdings increased from 2 to 3 for an increase of 1. Sold All: 18 Reduced: 35 Increased: 42 New Position: 18.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company has market cap of $1.17 billion. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. It currently has negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit.

The stock decreased 0.39% or $0.13 during the last trading session, reaching $33.18. About 42,533 shares traded. Genomic Health, Inc. (NASDAQ:GHDX) has declined 2.07% since April 17, 2017 and is downtrending. It has underperformed by 13.62% the S&P500.

Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on May, 8. They expect $-0.08 EPS, down 14.29 % or $0.01 from last year’s $-0.07 per share. After $0.08 actual EPS reported by Genomic Health, Inc. for the previous quarter, Wall Street now forecasts -200.00 % negative EPS growth.

Camber Capital Management Llc holds 4.11% of its portfolio in Genomic Health, Inc. for 2.46 million shares. Baker Bros. Advisors Lp owns 13.78 million shares or 4.09% of their US portfolio. Moreover, Emory University has 1.85% invested in the company for 62,926 shares. The Virginia-based Motley Fool Asset Management Llc has invested 0.98% in the stock. Tributary Capital Management Llc, a Colorado-based fund reported 318,887 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 13 sales for $3.40 million activity.

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

Ratings analysis reveals 13% of Genomic Health’s analysts are positive. Out of 8 Wall Street analysts rating Genomic Health, 1 give it “Buy”, 3 “Sell” rating, while 4 recommend “Hold”. The lowest target is $25.0 while the high is $42.0. The stock’s average target of $32 is -3.56% below today’s ($33.18) share price. GHDX was included in 10 notes of analysts from October 20, 2017. JP Morgan downgraded Genomic Health, Inc. (NASDAQ:GHDX) on Wednesday, December 13 to “Underweight” rating. The rating was maintained by Jefferies with “Hold” on Friday, October 20. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Hold” rating by Piper Jaffray on Thursday, March 8. The company was maintained on Friday, March 9 by Canaccord Genuity. Canaccord Genuity maintained the shares of GHDX in report on Wednesday, November 15 with “Buy” rating. Canaccord Genuity maintained Genomic Health, Inc. (NASDAQ:GHDX) rating on Tuesday, January 16. Canaccord Genuity has “Buy” rating and $42.0 target. The firm has “Hold” rating given on Wednesday, December 20 by William Blair. The rating was downgraded by J.P. Morgan on Wednesday, December 13 to “Sell”.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: